Skip to main content
. 2021 Dec;379(3):343–357. doi: 10.1124/jpet.121.000845

Fig. 2.

Fig. 2.

In vitro synergy studies of berzosertib and TMZ combination in established GBM cell lines. Increasing concentrations of berzosertib (0–1000 nM) and TMZ (0–300 μM) combinations tested for in vitro synergy in (A) U87, (B) U251, (C) GBM22, (D) U251-CV, and (E) U251 MGMT overexpressing cell lines (U251-MGMT). (F) MGMT status, p53 status, and synergy scores for all the tested cell lines.